Biomarkers of response to therapy in oesophago-gastric cancer.

Regulation of the yjjQ-bglJ operon, encoding LuxR-type transcription factors, and the divergent yjjP gene by H-NS and LeuO.

Current status of excision repair cross complementing-group 1 (ERCC1) in cancer.

Repression by binding of H-NS within the transcription unit.

Enhancement of bioavailability and anthelmintic efficacy of albendazole by solid dispersion and cyclodextrin complexation techniques.

Intraperitoneal gene therapy.

Tyrosine kinase inhibitors and cancer therapy.

Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy.

The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer.

DNA repair inhibition: a selective tumour targeting strategy.

Independent regulation of H-NS-mediated silencing of the bgl operon at two levels: upstream by BglJ and LeuO and downstream by DnaKJ.

Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.

Isolation of a small molecule inhibitor of DNA base excision repair.

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.

Direct one-pot conversion of acylated carbohydrates into their alkylated derivatives under heterogeneous reaction conditions using solid NaOH and a phase transfer catalyst.